API | crizanlizumab

crizanlizumab (Adakveo) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA

AACT

Active Ingredient History

NOW

Crizanlizumab, sold under the brand name Adakveo among others, is a monoclonal antibody medication that binds to P-selectin. It is a medication used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. It is given by injection into a vein. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Drug Pricing (per unit)

United States

$176.4250 - $233.3450

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

selg1

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Anemia, Sickle Cell (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Anemia, Sickle Cell (Phase 4)

COVID-19 (Phase 2)

Livedoid Vasculopathy (Phase 2)

Priapism (Phase 2)

Primary Myelofibrosis (Phase 1/Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 14
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue